Strs Ohio Castle Biosciences Inc Transaction History

Strs Ohio

$24.7 Billion
Q1 2024

A detailed history of Strs Ohio transactions in Castle Biosciences Inc stock. As of the latest transaction made, Strs Ohio holds 22,700 shares of CSTL stock, worth $494,179. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,700

Previous 24,100 5.81%

Holding current value

$494,179

Previous $520,000 3.46%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$18.06 - $25.3 $25,284 - $35,420	-1,400 Reduced 5.81%	22,700 $502,000
Q4 2023 Jan 30, 2024	SELL	$12.19 - $22.43 $48,760 - $89,720	-4,000 Reduced 14.23%	24,100 $520,000
Q2 2023 Jul 31, 2023	BUY	$11.66 - $26.0 $11,660 - $26,000	1,000 Added 3.69%	28,100 $385,000
Q1 2023 Aug 02, 2023	SELL	$19.47 - $28.49 $19,470 - $28,490	-1,000 Reduced 3.56%	27,100 $615,000
Q1 2023 Apr 27, 2023	BUY	$19.47 - $28.49 $130,448 - $190,883	6,700 Added 32.84%	27,100 $615,000

Q2 2022 Jul 25, 2022	BUY	$16.0 - $45.99 $281,600 - $809,424	17,600 Added 628.57%	20,400 $447,000
Q3 2021 Oct 22, 2021	SELL	$60.13 - $77.6 $264,572 - $341,440	-4,400 Reduced 61.11%	2,800 $186,000
Q2 2021 Jul 26, 2021	SELL	$50.07 - $76.78 $275,385 - $422,290	-5,500 Reduced 43.31%	7,200 $527,000
Q1 2021 Apr 23, 2021	SELL	$58.92 - $97.33 $11,784 - $19,466	-200 Reduced 1.55%	12,700 $869,000
Q3 2020 Dec 14, 2020	BUY	$38.47 - $52.03 $457,793 - $619,157	11,900 Added 1190.0%	12,900 $663,000
Q3 2019 Oct 21, 2019	BUY	$18.09 - $27.92 $18,090 - $27,920	1,000 New	1,000 $18,000

Others Institutions Holding CSTL

# of Institutions

162

Shares Held

25.3M

Call Options Held

82.2K

Put Options Held

150K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $572M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account